Title: *Burkholderia thailandensis* methylated hydroxy-alkylquinolines: biosynthesis and antimicrobial activity in co-culture experiments

Authors: Jennifer R Klaus^{a, §}, Charlotte Majerczyk^{b, §}, Natalie A. Eppler^{b†}, Patrick Ball^a, Marie-Christine Groleau^c, Kyle L. Asfahl^d, Nicole E. Smalley^d, Hillary Hayden^d, Marianne Piochon^c, Ajai A. Dandekar^d, Charles Gauthier^c, Eric Deziel^c, and Josephine R. Chandler^b#

[§]Equal contributors

Affiliations:

^aDepartment of Molecular Biosciences, University of Kansas, Lawrence KS 66045;

^bDepartment of Biology, Oregon State University – Cascades, Bend, OR 97702

^cINRS-Centre Armand Frappier Santé Biotechnologies, Laval (Québec) H7V 1B7,

Canada;

^dDepartment of Microbiology, University of Washington, Seattle WA 98195

†Current address: Department of Microbiology, University of Kansas Medical Center,

Kansas City KS 66160

Running title: Methylated alkylquinolines in Burkholderia thailandensis

Address correspondence to:

Josephine R. Chandler University of Kansas Department of Molecular Biosciences 1200 Sunnyside Ave Lawrence, KS 66045 jrchandler@ku.edu

ABSTRACT (179/250 words)

The bacterium *Burkholderia thailandensis* produces an arsenal of secondary metabolites that have diverse structures and roles in the ecology of this soil-dwelling bacterium. In liquid co-culture experiments, B. thailandensis secretes a previously unstudied antimicrobial that nearly eliminates another soil bacterium, *Bacillus subtilis*. To identify the antimicrobial, we used a transposon mutagenesis approach. This screen identified antimicrobial-defective mutants with insertions in the *hmqA*, C and F genes involved in biosynthesis of a family of quinolones called 3-methyl-4-hydroxy-2-alkenylquinolines (HMAOs), which are related to the *Pseudomonas aeruginosa* 4-hydroxy-2alkylquinolines (HAOs). Insertions also occurred in a previously uncharacterized gene BTH II1576. We confirm that BTH II1576 is involved in generating N-oxide HMAQ (HMAQ-NO) in *B. thailandensis* and that HMAQ-NOs are sufficient to eliminate *B*. subtilis in co-cultures. Moreover, synthetic HMAQ-NO is ~50-fold more active than HMAO. Both the methyl group and the length of the carbon side chain account for high activity of HMAQ-NO against B. subtilis. The results provide new information on the biosynthesis and activities of HMAQs and reveal new insight into how these molecules might be important for the ecology of *B. thailandensis*.

IMPORTANCE (120 words)

The soil bacterium *Burkholderia thailandensis* produces methylated alkylquinolones, which are a family of relatively unstudied molecules related to the alkylquinolones of *Pseudomonas aeruginosa*. Several of the methylated alkylquinolones have antimicrobial activity against other species. We show *N*-oxidated methyl-alkenylquinolone is particularly antimicrobial and is sufficient to kill *Bacillus subtilis* in co-cultures, and requires a previously unstudied protein HmqL for biosynthesis. These results also provide new information about the biology of alkyl-quinolones, particularly the methylated alkylquinolones, which are unique to *B. thailandensis*. This study also has importance for understanding *B. thailandensis* secondary metabolites and has implications for potential therapeutic development.

INTRODUCTION

The saprophytic β-Proteobacteria *Burkholderia thailandensis* is closely related to two pathogens, *B. pseudomallei* and *B. mallei*, which are the causative agents of melioidosis and glanders, respectively (1, 2). *B. pseudomallei* is also a saprophyte and causes respiratory or skin infections in humans following exposure to organisms in the environment, such as through skin contact with soil (3). *B. mallei* is a host-adapted pathogen and is spread to humans from horses or another animal where it is endemic in some regions (4). Because *B. pseudomallei* and *B. mallei* are Tier 1 Select Agents and require handling in BSL-3-level laboratory conditions, *B. thailandensis* is often used as a surrogate to study biology and virulence mechanisms of these pathogens (5). The development of versatile genetic techniques (6-9) and improvements in mouse models of melioidosis (10) have greatly improved the ability to study the biology of this relatively understudied group.

There has been much interest in elucidating the arsenal of small molecules produced by *B. thailandensis*, where there are at least 13 polyketide synthesis (PKS) gene clusters. Although many of these metabolites have now been identified, only a few have been studied in much detail. One of the best studied is bactobolin (12, 13), which blocks translation by binding to a unique site in the 50S ribosomal subunit (14). Another PKS antibiotic is malleilactone (15, 16), and malleicyprol, a more toxic product of the malleilactone biosynthetic gene cluster (17), which contribute to virulence of *B. pseudomallei* (18). *B. thailandensis* also produces thailandenes, a group of polyenes with activity against Gram-positive bacteria (19). As with many bacterial natural products, malleilactone and thailandenes are not produced in standard laboratory conditions (15, 16, 19). Studies of these molecules were possible through genetic (15, 16) or chemical (20) elicitation of the gene clusters or through phenotype-based screening approaches (19).

Most of the PKS gene clusters are unique to this group of *Burkholderia*. A few of them have analogous biosynthesis pathways in other *Burkholderia* species or even beyond the *Burkholderia*. For example, the *hmqABCDEFG* operon coding for enzymes responsible for the biosynthesis of a family of antimicrobial quinolones named 4-hydroxy-3-methyl-2-alkenylquinolines (HMAQs) are found in *B. pseudomallei* and other

members of the *Burkholderia* genus such as *Burkholderia ambifaria* (21). The products of the *hmq* genes have varying carbon chain lengths and the relative abundance of these molecules differs between species. The *hmq* operon is homologous to the *pqs* operon found in *P. aeruginosa*. The molecules produced by *Burkholderia* also differ from that of *P. aeruginosa* in that most bear a methyl group at the 3' position and possess an unsaturated aliphatic side chain, which are linked to the presence of the additional *hmqG* and *hmqF* genes (22). The main product of the *P. aeruginosa* pqs operon, 4-hydroxy-2-heptylquinoline or HHQ is converted to 3,4-dihydroxy-2-heptylquinoline or PQS by the enzyme PqsH. Both are involved in quorum sensing in *P. aeruginosa* and are detected by the MvfR regulator (also called PqsR) (23). No homologs of the *pqsH* and *mvfR* genes are found in *Burkholderia* (22).

We are interested in the small molecule repertoire of *B. thailandensis* as an avenue to better understand its biology and make new discoveries on natural product biosynthesis. We observed that *B. thailandensis* culture fluid has significant antimicrobial activity that is not due to bactobolin, the only other known antimicrobial produced in these conditions. This bactobolin-independent activity was isolated to the *hmq* gene cluster using an approach involving transposon mutagenesis and screening for mutants exhibiting reduced antimicrobial activity. Purified and synthetic hydroxy-alkylquinoline derivatives were assessed for their antimicrobial properties including two of the most abundant products, 3-methyl-4-hydroxy-2-alkenylquinoline (HMAQ) and the *N*-oxide derivative of HMAQ (HMAQ-NO). The screen also confirmed the involvement of *hmqL* in the biosynthesis of the methylated quinolones produced by *Burkholderia*.

METHODS

Bacterial culture conditions and reagents. Bacteria were grown in Luria-Bertani (LB) broth (10 g tryptone, 5 g yeast extract, and 5 g NaCl per liter) supplemented with 50 mM morpholinepropanesulfonic acid (MOPS) where indicated, in M9 minimal medium supplemented with 0.4% glucose and 10 mM *para*-chloro-phenylalanine (*p*-Cl-Phe; Sigma) for *B. thailandensis* counterselection during mutant construction, or using DM media (0.25X M63 salts, 1 mM MgSO₄, 0.4% glycerol, 0.2% glucose, 1 µg/mL thiamine, and 40 μ g/mL each of leucine, isoleucine, valine, tryptophan, glutamic acid, and glutamine) for transformation of PCR-generated products. All B. thailandensis growth was at 30 °C unless otherwise indicated, all E. coli and Burkholderia ambifaria growth was at 37 °C. 4-Hydroxy-2-heptylquinoline (HHQ) was purchased from Sigma (cat. SML0747). 4-Hydroxy-2-heptylquinoline N-oxide (HQNO) was purchased from Cayman chemicals (cat. 15159). 4-Hydroxy-3-methyl-2-nonenylquinoline (HMNQ) was purified from B. thailandensis E264 cultures as described previously (22). For selection, trimethoprim was used at 100 µg/mL, gentamicin was used at 100 µg/mL, kanamycin was used at 500 µg/mL (B. thailandensis) or 50 µg/mL (E. coli), tetracycline was used at 225 µg/mL (B. ambifaria), and NaCl was used at 5% (for inhibiting B. thailandensis in co-culture enumerations). Isopropyl β -D -1-thiogalactopyranoside (IPTG) was added at 1mM final concentration to cultures and plates, when appropriate. Genomic DNA, PCR and DNA fragments, and plasmid DNA were purified using a Puregene Core A kit, plasmid purification miniprep kit, or PCR cleanup/gel extraction kits (Qiagen or IBI-MidSci) according to the manufacturer's protocol.

Genetic manipulations. All bacterial strains, plasmids, and primers used in this study are listed in Tables S1-S2. We used wild type and mutant derivatives of *B. thailandensis* strain E264 (5). We used *B. ambifaria* strain HSJ1 (22), and *E. coli* strain DH5 α for genetic manipulations (Invitrogen). The *B. thailandensis* bactobolin-defective mutant BD20 has a deletion of the bactobolin biosynthesis gene *btaK* as described previously (12). The *B. thailandensis hmqA* mutant was constructed using allelic exchange using methods described previously (6) and plasmid pMCG19. pMCG19 was constructed by first amplifying *hmqA* from the *B. thailandensis* E264 genome using primers hmqAfor

and hmqArev containing HindIII and KpnI cleavage sites, respectively. The PCR product was digested with HindIII and KpnI and ligated to HindIII-KpnI-cut pEX18Tp-PheS (9). The chloramphenicol resistance cassette was amplified from pACYC184 (REF) using primers CmFPstI and CmRPstI each containing the PstI cleavage site and ligated to the PstI site inside the *hmqA* gene in pEX18Tp-PheS-*hmqA* to make pMCG19.

B. thailandensis BTH_II1576 (*hmqL*) mutants were made by transforming a PCRamplified BTH_II1576::*dhfr* allele from transposon mutant #56 into the genome of strain BD20 using PCR transformation using a modified protocol similar to Thongdee *et al.* (24). Briefly, shaking *B. thailandensis* cultures were grown at 37 °C to an optical density (OD₆₀₀) of 0.5, concentrated 20-fold, and distributed to 5 aliquots of 50 µL. Each aliquot was mixed with 5 µL of gel-extracted *hmqL::dhfR* PCR product (amplified using hmqL-Tn-for2 and hmqL-Tn-rev2 primers). The cell-DNA mixture was spotted onto solid DM media (DM liquid media with 1.5% agar) and incubated at 37 °C for 48 h. The DM plate growth was scraped up and collected, washed twice with DM, suspended in 200 µL of DM, and spread onto LB agar containing trimethoprim. Mutant strains were verified by PCR-amplifying the mutated region and sequencing the PCR product.

For ectopic expression of *hmqL* in *B. thailandensis*, this gene was placed under control of the IPTG-inducible *lac* promoter in pUC18miniTn7T-LAC-Km (25). To construct this plasmid, we amplified *hmqL* from the *B. thailandensis* E264 genome using primers hmqL-ORF-F-SacI and hmqL-ORF-R-HindIII that incorporated the SacI and HindIII restriction enzyme sites, respectively, into the product. The amplicon was cut with SacI and HindIII and ligated to SacI- and HindIII-digested pUC18miniTn7T-Kan-*Plac-malR* (25) to make pUC18miniTn7T-P*lac-hmqL* (entirely removing the *malR* gene). This plasmid was used to transform competent *B. thailandensis* with the helper plasmid pTNS2 as described previously (26). We used PCR to verify insertion of the *Plac-hmqL* cassette *into* the *attn7* site near *glmS1*.

We used plasmid pME6010 (27) for expressing the *hmqL* gene from *B*. *thailandensis* in *B. ambifaria*. The *hmqL* gene was amplified from the *B. thailandensis* E264 genome using primers hmqL-F and hmqL-R that incorporated the BglII and KpnI sites into the amplicon. The product was cut with BglII and KpnI and ligated to BglIIand KpnI-digested pME6010 to make pMCG17. *B. ambifaria* strains with pME6010

7

plasmids were constructed by electroporation as previously described for *B. thailandensis* (6).

Liquid co-cultures. Logarithmic-phase overnight starter cultures (OD_{600} between 0.5 and 1.5) of *B. subtilis* and *B. thailandensis* were diluted to an OD_{600} of 0.05 and combined at a starting ratio of 1:1 in a 10 mL volume of LB in 125 mL baffled flasks. The flasks were incubated with shaking at 250 rpm at 37 °C for 24 h before serially diluting and plating on LB agar plates containing gentamicin (to inhibit *B. subtilis*) or 5% NaCl (to inhibit *B. thailandensis*) and IPTG as appropriate to enumerate bacterial colony forming units (CFU).

Antimicrobial activity assays. Antimicrobial activities of *B. thailandensis* culture fluid were assayed using disc diffusion (for filtered fluid) or outgrowth diffusion (for unclarified fluid) methods. For both methods, inocula for each of the *B. thailandensis* strains and *B. subtilis* were prepared by suspending a colony from an LB agar plate into LB broth and growing overnight at 30 °C with shaking. *B. subtilis* overnight culture (100 μ L) diluted 1:100 was spread onto an LB agar plate and allowed to dry. The *B. thailandensis* cultures were either centrifuged and filter sterilized through a 0.2 μ m membrane and used to saturate a sterile filter disc placed on the *B. subtilis* lawn (for disc diffusion), or spotted directly onto the *B. subtilis* lawns (for outgrowth diffusion), and plates were incubated at 30 °C for 24 h before observing zones of clearing of the *B. subtilis* lawns. The outgrowth assays were also conducted similarly on LB agar plates containing 5% NaCl, which inhibits growth of the *B. thailandensis* strains.

The antimicrobial activities of purified, commercial, or synthesized quinoline compounds were assessed using a minimum inhibitory concentration (MIC) assay according to a modified protocol from the 2018 guidelines of the Clinical and Laboratory Standards Institute (CLSI). Inocula for each test organism were prepared by suspending a colony from an LB agar plate into Tryptic Soy Broth (TSB) and growing for 3-5 h at 37 °C with shaking, then adjusting the culture turbidity in TSB to an OD₆₀₀ of 0.25, roughly the equivalent of a 1.0 McFarland Standard (3×10^8 CFU per mL). These cell suspensions were used as inocula for microtiter MIC assays. 2.5 µL inoculum, which corresponded to 1×10^6 cells, was added to a 100 µL well containing diluted in cationadjusted Mueller-Hinton II broth, and these were incubated with shaking for 24 h at 37 °C. The MIC was defined as the lowest concentration of compound (µg/mL) in which bacterial growth in the well was not visible.

Transposon mutagenesis and screen. Transposon mutagenesis was performed using the EZ-Tn5TM <DHFR-1>Tnp TransposomeTM Kit (Epicentre), according to manufacturer's specifications. Briefly, electrocompetent cells of the B. thailandensis bactobolindefective mutant BD20 were generated by growing cultures to mid-exponential phase $(OD_{600} 0.5-0.7)$, collecting with centrifugation, washing the cell pellet 3 times in ice-cold 0.5 M sucrose (using 25% the volume of the original culture), and then resuspending the cell pellet in 100 µL ice-col 0.5 M sucrose. Immediately, 1 µL of the transposome was added to 50 µL of electrocompetent cells in a 0.2 mm electroporation cuvette. This was transformed with the Bio-Rad Gene Pulser II (settings 25 μ F, 200 Ω , 2.5 kV), and the cells were immediately recovered in 1 mL LB broth with shaking at 37 °C for 1 h. At the end of the recovery, the culture was diluted 1:25, and 100 µL samples were plated on 20 LB plates with trimethoprim selection (100 μ g/mL). The plates were incubated overnight at 37 °C. The following day, single colonies were patched onto plates prepared with B. subtilis to screen for antimicrobial activity. Due to the scale required for the screen, we added B. subtilis directly to molten agar used to pour plates, as opposed to spreading B. subtilis lawns after pouring. To prepare the B. subtilis-agar media, we added 1.43 mL of a stationary phase B. subtilis culture (overnight growth) to 1 L of cooled but molten LB agar media (55-60 °C), mixed gently and poured. After a brief period to solidify and dry, plates were used to patch colonies isolated from the EZ-Tn5TM <DHFR-1> transposon mutagenesis. Patched plates were incubated overnight at 30 °C prior to identifying mutants defective for antimicrobial activity, as determined by reduced zones of B. subtilis growth inhibition compared with the *B. thailandensis* parent. Identified candidates were streaked for single B. thailandensis colonies on LB with gentamicin to prevent B. subtilis growth, and re-tested in our assay to confirm the phenotype. Confirmed mutants with no apparent growth defects were subjected to whole genome sequencing.

Identification of transposon insertion sites. The transposon insertion locations of five transposon mutants (#7, 14, 31, 32, and 56) were determined by whole-genome resequencing. DNA isolated from the transposon mutant strains was used to make sequencing libraries with 300-bp inserts. The libraries were sequenced on an Illumina MiSeq System using the NEBNext Ultra II kit, generating approximately one million 200-bp paired-end reads per sample. The paired-end reads were assembled *de novo* into draft genomes using the SPAdes assembler with standard settings (28). For each de novo assembly, the contig with Tn5 transposon sequence was located using a nucleotide search in the BLAST+ command line suite with individual blast databases for each transposon mutant (29). Clustal Omega was then used to precisely locate the sequence context of Tn5 insertion in each contig of interest (30). Genomic context for individual transposon insertions was then determined by blasting up- and down-stream sequences against a database of all B. thailandensis E264 gene sequences to identify specific loci interrupted by Tn5 insertion. Finally, the raw reads were aligned to the *B. thailandensis* E264 ATCC700388 reference genome (NC 007650, NC 007651 downloaded from burkholderia.com) using Strand NGS (Bangalore, India) software v 3.1.1 to confirm the insertion locus in each mutant. The remaining four transposon mutants (#9, 27 63, and 68) were assessed by PCR amplifying regions of the *hmg* locus (primers given in **Table S2**). Mutations identified by either method were verified by Sanger sequencing of PCR-amplified products.

HMAQ and HMAQ-NO measurements from bacterial cultures. To measure the production of HMAQ and HMAQ-NO in *B. thailandensis* cultures, samples were prepared by diluting stationary-phase *B. thailandensis* cultures to an OD₆₀₀ of 0.05 into 5 mL of LB in 18 mm culture tubes and growing the cultures for 18 h with shaking at 250rpm at 30°C or as otherwise described. Where necessary, 1 mM IPTG was added to the LB for the 18 h cultures. Sample preparation and LC-MS analysis were performed as described by Lepine *et al.* (31) with minor modifications. Briefly, for each sample, 300 μ L of grown culture was mixed with 300 μ L of HPLC-grade methanol containing 4 ppm of 5,6,7,8-tetradeutero-4-hydroxy-2-heptylquinoline (HHQ-d₄; 4 ppm) as an internal standard, vortexed and centrifuged for 5 min at maximum speed in an Eppendorf

centrifuge. The supernatant was removed for analysis. Samples were analyzed by highperformance liquid chromatography (HPLC; Waters 2795, Mississauga, ON, Canada) equipped with a C8 reverse-phase column (Eclipse XDB-C8, Agilent Technologies, Mississauga, ON, Canada), and the detector was a mass spectrometer (Quattro Premier XE, Waters). Analyses were carried out in the positive electrospray ionization (ESI+) mode.

Synthesis of *N***-oxide hydroxyquinolines.** HMAQ-NOs were synthesized as previously described (32) from corresponding HMAQs in which the quinolone scaffold was built *via* the Conrad-Limpach approach (33). Briefly, aniline was condensed with diethyl 2-methyl-3-oxosuccinate and the resulting diester was cyclized under acidic conditions. Reduction of the quinolone ester followed by halogen substitution led to 2-chloromethyl-3-methylquinolin-4(1*H*)-ones, which were subjected to Suzuki-Miyaura cross-coupling (34) with commercially available alkenylboronic acid pinacol esters to provide HMAQs. Then, they were converted into corresponding ethyl carbonates, oxidized with *m*CPBA, and deprotected to yield HMAQ-NOs (35). The structure of HMAQ-NOs were confirmed by HRMS as well as 1D and 2D NMR analysis.

RESULTS

Antimicrobial activity of B. thailandensis bactobolin mutants

Initial liquid co-culture experiments with *B. thailandensis* and *B. subtilis* showed that *B. thailandensis* has a strong growth advantage over *B. subtilis*. The growth advantage was so substantial that after overnight liquid co-culture with *B. thailandensis*, *B. subtilis* was below the limit of detection ($<10^2$ cells per mL). This result was not solely attributed to bactobolin, as a bactobolin-defective *B. thailandensis* mutant (BD20) also had the same growth advantage over *B. subtilis* (**Fig. 1A**). This observation led to the hypothesis that *B. thailandensis* has a previously uncharacterized antimicrobial activity against *B. subtilis* that is not mediated by bactobolin. To further explore this hypothesis, culture fluids of several *B. thailandensis* strains were harvested and tested for antimicrobial activity (**Fig. 1B**). As previously observed, filter-sterilized culture fluids of

wild-type *B. thailandensis* saturated to a paper filter disc placed on a lawn of *B. subtilis* caused a zone of growth inhibition around the filter disc, whereas there was no growth inhibition observed with the bactobolin-defective BD20 strain (**Fig. 1B**, top panel). However, unprocessed culture fluid of both strains (wild-type and BD20), which had not gone through the filter sterilization process, demonstrated antimicrobial activity (**Fig. 1B**, middle and bottom panels). This observation (i.e. that only unprocessed culture fluid had bactobolin-independent antimicrobial activity) could be explained by several possible hypotheses: first, that the filter sterilization process removes or inactivates antimicrobial activity; and second, that antimicrobial activity requires live cells. In support of the first hypothesis, the antimicrobial activity was observed in the absence of viable *B. thailandensis* bactobolin mutant cells; unprocessed Bt Bacto⁻ culture fluids had activity against *B. subtilis* when added directly to high-salt LB agar plates, which are conditions that do not allow for *B. thailandensis* growth (**Figure 1B, bottom panel**). Together, these results suggest *B. thailandensis* produces an antimicrobial other than bactobolin, which is eliminated by filter sterilization.

Transposon mutagenesis, isolation and identification of antimicrobial-defective mutants

To identify the genes required for antimicrobial activity, we used a mutagenesis and screening approach. First, we mutagenized the *B. thailandensis* bactobolin-defective mutant BD20 with a transposon containing the trimethoprim resistance gene dhfR (Tn5::dhfR). Next, we screened the mutants (~10,000) using a high-throughput method to assess antimicrobial activity (for experiment overview see **Fig. S1**). Briefly, we added *B. subtilis* cells to cooled molten agar and mixed gently before pouring into plates. After the media solidified, single isolated colonies (ie, transposon mutants) were patched onto the plates. The next day, plates were assessed for zones of inhibition. *B. thailandensis* patches demonstrating reduced zones of inhibition compared with the *B. thailandensis* bactobolin-defective parent were re-isolated for further study. We initially identified 60 antimicrobial activity against *B. subtilis* (**Fig. 2A**) with no observable growth defects (**Table S3**). These were mutants 7, 9, 14, 27, 31, 32, 56, 63, and 68.

To identify the location of the transposon mutations, we used an approach of whole-genome sequencing using an Illumina platform, followed by PCR amplification and Sanger sequencing to verify mutations in both the Illumina-sequenced isolates and the un-sequenced isolates. Of the nine mutants identified in our screen, seven had insertions in the *hmqABCDEFG* operon (BTH_II1929 - 1935, **Table 2**). The other two mutants had disruptions in a previously unstudied gene, BTH_II1576, which is predicted to encode a monooxygenase. To verify the *hmq* locus and BTH_II1576 contribute to the antimicrobial defects observed for the transposon mutants, we disrupted *hmqA* or BTH_II1576 in the bactobolin-defective BD20 strain using homologous recombination. Both gene disruptions caused a similar defect in *B. subtilis* growth inhibition as observed with the transposon mutants (**Fig. 2B**), supporting that the *hmq* genes and BTH_II1576 are important for the bactobolin-independent antimicrobial activity of *B. thailandensis*.

Identification and activities of hmq gene products

The *hmq* operon is responsible for the production of 4-hydroxy-3-methyl-2alkenylquinolines or HMAQs (22). The biosynthesis of HMAQs is analogous to biosynthesis of the related 4-hydroxy-2-alkylquinolines (HAQs) in Pseudomonas *aeruginosa* by the pqs gene products (21, 36)(**Fig. 3**). Both the pqs and hmq gene products use anthranilic acid and fatty acid precursors to generate HAQs, which include molecules with unsaturated or saturated side chains and an N-oxide derivative (Fig. 3). One notable difference is that HMAQs have a methyl group, which is added by HmqG (22). The most abundant HMAQ congener in *B. thailandensis* E264 is HMAQ with an unsaturated C9 side chain (HMAQ-C9:2'). To test whether HMAQ-C9:2' is absent in our transposon mutants, we measured HMAQ-C9:2' in culture fluid using a liquid chromatography-tandem mass spectrometry (LC-MS/MS) approach to find a product with the expected m/z of 284. Consistent with previous results (22, 37), transposon mutants with insertions in *hmqA* and *hmqF* had no detectable HMAQ-C9:2' (<0.05) µg/mL). We also detected no HMAQ-C9:2' in *hmqC* mutants, consistent with the proposed role of *hmqC* in HMAQ biosynthesis (22). The BD20 parent strain and BTH_II1576 transposon mutants both produced this HMAQ congener (measured at 5-8 $\mu g/mL$).

We also tested the activity of HMAQ-C9 against *B. subtilis* using a standard minimum inhibitory concentration (MIC) assay. The MIC of purified HMAQ-C9 against *B. subtilis* was 50 µg/mL (**Table 2**). HMAQ-C9 also inhibited *Staphylococcus aureus* growth (MIC 25 µg/mL). We did not detect any antimicrobial activity against *Escherichia coli* or *Pseudomonas aeruginosa* (MIC >200 µg/mL HMAQ-C9). Of note, HMAQ-C9 in *B. thailandensis* cultures is ~5-fold less than the amount needed to inhibit *B. subtilis* growth (50 µg/mL), suggesting HMAQ-C9 alone is not sufficient for killing *B. subtilis* in our co-culture experiments. Instead, we hypothesized that the killing activity involves another product of the *hmq* genes.

Biosynthesis and antimicrobial activity of HMAQ-NO

The protein product of BTH II1576 shares 52% amino acid sequence identity to that of the *P. aeruginosa* PqsL protein involved in HAQ biosynthesis. PqsL synthesizes *N*-oxide derivatives (HAQ-NO) from a precursor of HAQ, 2-aminobenzoylacetate (2-ABA) (38) (Fig. 3, left column). We hypothesized that BTH II1576 is similarly involved in biosynthesis of N-oxide HMAQ (HMAQ-NO) in B. thailandensis (Fig. 3, right column). To test this hypothesis, we used LC-MS/MS to measure HMAQ-NO in the BTH_II1576 transposon mutants. We measured HMAQ-NO with an unsaturated C9 or C7 side chain, which are two abundant congeners in *B. thailandensis* E264. Both of the BTH II1576 mutants and our constructed BD20 BTH II1576 mutant had undetectable HMAQ-NO-C9 (<0.05 μ g/mL), whereas the BD20 parent had detectable levels (1.5 \pm 0.5 μ g/mL). We also ectopically expressed BTH_II1576 from an IPTG-inducible lac promoter from the neutral glmS1 site in the engineered BTH_II1576 mutant genome, and compared HMAQ-NO-C9 and antimicrobial activities in this strain with an empty *lac*-promoter containing mutant or BD20 parent (Fig. 4). IPTG induction of BTH_II1576 in the mutant restored production of HMAQ-NO (Fig. 4A) and increased the zone of inhibition of B. subtilis in colony outgrowth experiments (Fig. 4B), supporting that BTH II1576 is important for each of these processes. Further, BTH_II1576 induction significantly decreased HMAQs, supporting that the product of BTH_II1576 uses HMAQ as the substrate to generate

HMAQ-NO. Together, our results confirm that the BTH_II1576 product is analogous to PqsL in HAQ-NO biosynthesis and is appropriately named as *hmqL*.

Because HmqL generates HMAQ-NO and is important for antimicrobial activity observed in *B. thailandensis* cultures, we tested the hypothesis that HMAQ-NO has antimicrobial activity against *B. subtilis*. We assessed the sensitivity of *B. subtilis* to synthesized HMAQ-NO (HMAQ-NO-C9:2')(32). The MIC of HMAQ-NO-C9:2' was 0.75 µg/mL against *B. subtilis*. This MIC is below the measured concentration of HMAQ-NO in *B. thailandensis* cell cultures $(1.5 \pm 0.5 \mu g/mL)$, supporting the idea that HMAQ-NO is primarily responsible for the observed antimicrobial activity against *B. subtilis* in co-cultures with *B. thailandensis*. Interestingly, there was no difference in activity of HMAQ-NO and HMAQ against *S. aureus* (MIC 25 µg/mL). Differences in diffusion or target site availability could explain the differences in relative activities of these two molecules in each species.

Antimicrobial activities of structurally related alkylquinolones

We found it intriguing that HHQ and HQNO were much less active against *B. subtilis* than the respective HMAQ and HMAQ-NO molecules (**Table 2**). The difference in activity could be due to the difference in alkyl chain lengths. Alternatively, the presence of the methyl group in HMAQs could also affect the activity. To address the first possibility, we tested synthetic HMAQ-NO congeners with a C7 and C8 unsaturated alkyl chain against *B. subtilis*. Our results showed that the C7 and C8 HMAQ-NO molecules were 4- and 16-fold more active than HQNO (HAQ-NO-C7) against *B. subtilis,* respectively (**Table 2**). These results suggest both the methyl group and the carbon chain length contribute to the activity of HMAQ-NO against *B. subtilis,* with both methylation and longer chain lengths showing higher activities. In *S. aureus,* methylation increased activity of the C7 side chain *N*-oxide congener by 2-fold, but had no influence on the C9 congener (**Table 2**).

HMAQ-NO promotes competition in liquid co-cultures

Results of our transposon mutant analysis suggest *hmqL* and HMAQ-NO-C9 are important for the initial observation that *B. thailandensis* eliminates *B. subtilis* from liquid co-cultures. To test this hypothesis, we competed *B. subtilis* with *B. thailandensis* bactobolin-deficient BD20 containing either a single *hmqA* or *hmqL* mutation or a *hmqAhmqL* mutation in liquid co-culture experiments. Singly disrupting *hmqA* or *hmqL* nearly abolished the ability of *B. thailandensis* to kill *B. subtilis* (**Fig. 5A**). Further, a strain disrupted for both *hmqL* and *hmqA* showed killing defects similar to that of either single mutant, supporting that *hmqL* and *hmqA* are in the same biosynthetic pathway. The results also support that the HMAQ-NO molecule, or HMAQ-NO together with other products of this pathway, are key for killing in liquid co-cultures.

Our initial observations suggested the antimicrobial in *B. thailandensis* cultures was sensitive to filtration, thus, we also sought to test the sensitivities of HMAQ and HMAQ-NO to filtration. We measured concentrations of each of these molecules in unfiltered and filtered fluid from cell-free *B. thailandensis* cultures. We also determined the concentrations of these molecules in pelleted cells to determine whether they are primarily associated with the cell, similar to HAQs in *P. aeruginosa* (39, 40). We found that the percent HMAQs and HMAQ-NOs in the cell fraction was 91 ± 2 and 71 ± 3 , respectively. Thus, these molecules are highly cell associated. Furthermore, filtration further depletes molecules remaining in culture fluid to nearly undetectable levels (**Fig. 5B**). These results are consistent with the idea that HMAQs and HMAQ-NOs are removed by separation of the cells and filtration of the remaining fluid, providing an explanation as to how the activity of these molecules have been missed in prior experiments.

HMAQ biosynthesis in B. ambifaria

The *Burkholderia ambifaria* genome encodes an *hmq* operon homologous to that of *Burkholderia thailandensis* (22), however, *B. ambifaria* does not produce HMAQ-NOs (22), presumably because it does not have a homolog of *hmqL/pqsL*. We predicted that introducing the *B. thailandensis hmqL* to *B. ambifaria* would enable production of HMAQ-NO. To test this prediction, we introduced the *hmqL* gene to *B. ambifaria* on plasmid pME6010 (27). Because HMAQ biosynthesis is less well characterized in this species, we used combined measurements of all three C7, C8 and C9 congeners of HMAQs for our analysis. We observed that *B. ambifaria* (pME6010) had no detectable HMAQ-NO, as previously reported (22). However, *B. ambifaria* with pME6010-*hmqL* produced measurable levels of HMAQ-NO (**Fig. 6A**). This strain also had 100-fold less HMAQ than the plasmid-only strain (**Fig. 6A**), which is consistent with the idea that HmqL allows HMAQ-NO production in *B. ambifaria*. We also tested whether the expression of HmqL caused *B. ambifaria* to inhibit *B. subtilis* growth. We spotted unfiltered culture fluid from *B. ambifaria* with pME6010 or pME6010-*hmqL* onto a lawn of *B. subtilis*. Only cultures of the strain expressing *hmqL* could inhibit *B. subtilis* growth (**Fig. 6B**). Together, the results provide further support that HmqL is crucial for the production of the antimicrobial HMAQ-NO.

DISCUSSION & CONCLUSIONS

The antimicrobial properties of alkylquinolones date back to 1945, when an "antibiotic metabolite" was described in P. aeruginosa (41). Although the biosynthesis steps and biology of the alkylquinolones in *P. aeruginosa* have since been studied in detail, much less is known of those in *B. thailandensis* (22, 32, 42). Results of this study add new information to the known steps of biosynthesis of B. thailandensis alkylquinolines. Previous studies showed that enzymes analogous to PqsA-D in P. aeruginosa are involved in the synthesis of HMAQ from anthranilate in B. thailandensis (Fig. 3, right side). In *P. aeruginosa* the enzyme PqsL synthesizes PQS from HHQ. *B.* thailandensis has no PqsH enzyme and does not make PQS. B. thailandensis is also missing the PQS receptor gene, *mvfR*, consistent with the complete loss of this molecule from the B. thailandensis biosynthetic pathway. Our study provides an important new piece of information for building a model of alkylquinoline biosynthesis in B. thailandensis, which is the involvement on HmqL in N-oxide HMAQs biosynthesis. Our results also show how the HMAQ family of molecules contribute to the arsenal of compounds used by *B. thailandensis* to compete with other species and provide new insight into the activities of specific B. thailandensis HMAQ family congeners against other bacteria.

Like many toxins, hydroxy-quinolines have several known functions. In *P. aeruginosa*, where these molecules have perhaps best been studied, the *N*-oxide congener is a potent antimicrobial (43) and several of the hydroxy-quinolones are important for interspecies competition (44). The *pqs* biosynthesis genes also contribute to *P. aeruginosa* virulence (45) and PQS has immune modulatory activities (46). PQS is also a signal for cell density-dependent gene regulation (47) and regulates a variety of genes important for virulence (48). PQS also sequesters iron (39), which is a severely limited nutrient in host and other environments. We find it interesting that the *Burkholderias* do not have the enzyme responsible for generating PQS (PqsH, see **Fig. 3**) but instead have two additional genes encoding for enzymes responsible for the addition of an insaturation in the alkyl chain and a methyl group at the 3' position. In addition, *B. ambifaria* lacks the HmqL enzyme responsible for generating *N*-oxide quinolones, which are the most antimicrobial members of this family. The lack of PQS or any N-oxide analog in *B*.

ambifaria strongly supports that other products of this pathway have important functions that contribute to the survival of this species, although the biology of these other species is less well understood.

Our results support that the N-oxide HMAQs join the arsenal of antimicrobial compounds produced by *B. thailandensis* that promote its ability to inhibit growth of other species, such as bactobolin (13), malleilactone (15, 16), and thailandenes (19). This suite of diverse antimicrobials might be important for surviving competition with other microbes when space or other resources become limited. The loss of the *hmq* biosynthesis genes from the genome of the closely related host-adapted pathogen B. mallei supports a role of these genes in the saprophytic lifestyle of *B. thailandensis*. The current study demonstrates the N-oxide HMAQs are important for killing other species in several laboratory co-culture conditions. In addition to the N-oxide congeners, B. thailandensis produces a variety of HMAQs with side chains of varying length and saturation (22, 39). Although these other molecules had less potent antimicrobial activities (**Table 2**), it is possible they contribute to competition in other ways. A previous study showed that different species of hydroxy-alkyl quinolines used in combination can have synergistic antimicrobial effects on other bacteria, by acting on different cellular targets (49). Thus, the diversity of hydroxy alkyl quinolines produced by *B. thailandensis* might serve to enhance killing during competition or could be important for averting development of antibiotic resistance in competitors.

ACKNOWLEDGEMENTS

This work was supported by the NIH through grant R35GM133572 and a pilot award from the COBRE Chemical Biology of Infectious Disease Program (P20 GM113117) to J.R.C. and R01 GM125714 to A.A.D. N.A.E. was supported by a K-INBRE fellowship (P20 GM103418) and a KU Undergraduate Research Award. The KU sequencing facility is supported by P20 GM103418 and P20 GM103638. K.L.A. was supported by award ASFAHL19F0 from the Cystic Fibrosis Foundation. C.G. was supported by a Discovery grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) under award number RGPIN-2016-04950 and E.D. was supported by a grant from the Canadian Institutes of Health Research (CIHR) under award number MOP-142466. C. G. holds a Fonds de recherche du Québec – Santé (FRQS) Research Scholars Junior 2 Career Award. E. D. holds the Canada Research Chair in Sociomicrobiology.

REFERENCES

- 1. Cheng AC, Currie BJ. 2005. Melioidosis: epidemiology, pathophysiology, and management. Clin Microbiol Rev 18:383-416.
- 2. Whitlock GC, Estes DM, Torres AG. 2007. Glanders: off to the races with *Burkholderia mallei*. FEMS Microbiol Lett 277:115-22.
- 3. Dance DA. 2000. Ecology of *Burkholderia pseudomallei* and the interactions between environmental Burkholderia spp. and human-animal hosts. Acta Trop 74:159-68.
- 4. Van Zandt KE, Greer MT, Gelhaus HC. 2013. Glanders: an overview of infection in humans. Orphanet J Rare Dis 8:131.
- 5. Brett PJ, DeShazer D, Woods DE. 1998. *Burkholderia thailandensis* sp. nov., a *Burkholderia pseudomallei*-like species. Int J Syst Bacteriol 48 Pt 1:317-20.
- 6. Chandler JR, Duerkop BA, Hinz A, West TE, Herman JP, Churchill ME, Skerrett SJ, Greenberg EP. 2009. Mutational analysis of *Burkholderia thailandensis* quorum sensing and self-aggregation. J Bacteriol 191:5901-9.
- 7. Choi KH, DeShazer D, Schweizer HP. 2006. mini-Tn7 insertion in bacteria with multiple *glmS*-linked *attTn7* sites: example *Burkholderia mallei* ATCC 23344. Nat Protoc 1:162-9.
- 8. Lopez CM, Rholl DA, Trunck LA, Schweizer HP. 2009. Versatile dual-technology system for markerless allele replacement in *Burkholderia pseudomallei*. Appl Environ Microbiol 75:6496-503.
- 9. Barrett AR, Kang Y, Inamasu KS, Son MS, Vukovich JM, Hoang TT. 2008. Genetic tools for allelic replacement in *Burkholderia* species. Appl Environ Microbiol 74:4498-508.
- 10. Lawrenz MB, Fodah RA, Gutierrez MG, Warawa J. 2014. Intubation-mediated intratracheal (IMIT) instillation: a noninvasive, lung-specific delivery system. J Vis Exp doi:10.3791/52261:e52261.
- 11. Biggins JB, Kang HS, Ternei MA, DeShazer D, Brady SF. 2014. The chemical arsenal of *Burkholderia pseudomallei* is essential for pathogenicity. J Am Chem Soc 136:9484-90.
- 12. Duerkop BA, Varga J, Chandler JR, Peterson SB, Herman JP, Churchill ME, Parsek MR, Nierman WC, Greenberg EP. 2009. Quorum-sensing control of antibiotic synthesis in *Burkholderia thailandensis*. J Bacteriol 191:3909-18.
- 13. Seyedsayamdost MR, Chandler JR, Blodgett JA, Lima PS, Duerkop BA, Oinuma K, Greenberg EP, Clardy J. 2010. Quorum-sensing-regulated bactobolin production by *Burkholderia thailandensis* E264. Org Lett 12:716-9.

- Amunts A, Fiedorczuk K, Truong TT, Chandler J, Peter Greenberg E, Ramakrishnan V. 2015. Bactobolin A binds to a site on the 70S ribosome distinct from previously seen antibiotics. J Mol Biol 427:753-5.
- 15. Biggins JB, Ternei MA, Brady SF. 2012. Malleilactone, a polyketide synthase-derived virulence factor encoded by the cryptic secondary metabolome of *Burkholderia pseudomallei* group pathogens. J Am Chem Soc 134:13192-5.
- 16. Franke J, Ishida K, Hertweck C. 2012. Genomics-driven discovery of burkholderic acid, a noncanonical, cryptic polyketide from human pathogenic *Burkholderia* species. Angew Chem Int Ed Engl 51:11611-5.
- Trottmann F, Franke J, Richter I, Ishida K, Cyrulies M, Dahse HM, Regestein L, Hertweck C. 2019. Cyclopropanol Warhead in Malleicyprol Confers Virulence of Human- and Animal-Pathogenic Burkholderia Species. Angew Chem Int Ed Engl 58:14129-14133.
- 18. Moule MG, Spink N, Willcocks S, Lim J, Guerra-Assuncao JA, Cia F, Champion OL, Senior NJ, Atkins HS, Clark T, Bancroft GJ, Cuccui J, Wren BW. 2015. Characterization of new virulence factors involved in the intracellular growth and survival of *Burkholderia pseudomallei*. Infect Immun 84:701-10.
- Park JD, Moon K, Miller C, Rose J, Xu F, Ebmeier CC, Jacobsen JR, Mao D, Old WM, DeShazer D, Seyedsayamdost MR. 2020. Thailandenes, Cryptic Polyene Natural Products Isolated from Burkholderia thailandensis Using Phenotype-Guided Transposon Mutagenesis. ACS Chem Biol doi:10.1021/acschembio.9b00883.
- 20. Seyedsayamdost MR. 2014. High-throughput platform for the discovery of elicitors of silent bacterial gene clusters. Proc Natl Acad Sci U S A 111:7266-71.
- Coulon PML, Groleau MC, Deziel E. 2019. Potential of the Burkholderia cepacia Complex to Produce 4-Hydroxy-3-Methyl-2-Alkyquinolines. Front Cell Infect Microbiol 9:33.
- 22. Vial L, Lepine F, Milot S, Groleau MC, Dekimpe V, Woods DE, Deziel E. 2008. Burkholderia pseudomallei, B. thailandensis, and B. ambifaria produce 4-hydroxy-2alkylquinoline analogues with a methyl group at the 3 position that is required for quorum-sensing regulation. J Bacteriol 190:5339-52.
- 23. Diggle SP, Winzer K, Chhabra SR, Worrall KE, Camara M, Williams P. 2003. The *Pseudomonas aeruginosa* quinolone signal molecule overcomes the cell density-dependency of the quorum sensing hierarchy, regulates rhl-dependent genes at the onset of stationary phase and can be produced in the absence of LasR. Mol Microbiol 50:29-43.
- 24. Thongdee M, Gallagher LA, Schell M, Dharakul T, Songsivilai S, Manoil C. 2008. Targeted mutagenesis of *Burkholderia thailandensis* and *Burkholderia pseudomallei* through natural transformation of PCR fragments. Appl Environ Microbiol 74:2985-9.

- 25. Klaus JR, Deay J, Neuenswander B, Hursh W, Gao Z, Bouddhara T, Williams TD, Douglas J, Monize K, Martins P, Majerczyk C, Seyedsayamdost MR, Peterson BR, Rivera M, Chandler JR. 2018. Malleilactone Is a *Burkholderia pseudomallei* virulence factor regulated by antibiotics and quorum sensing. J Bacteriol 200.
- 26. Choi KH, Mima T, Casart Y, Rholl D, Kumar A, Beacham IR, Schweizer HP. 2008. Genetic tools for select-agent-compliant manipulation of *Burkholderia pseudomallei*. Appl Environ Microbiol 74:1064-75.
- 27. Heeb S, Itoh Y, Nishijyo T, Schnider U, Keel C, Wade J, Walsh U, O'Gara F, Haas D. 2000. Small, stable shuttle vectors based on the minimal pVS1 replicon for use in gramnegative, plant-associated bacteria. Mol Plant Microbe Interact 13:232-7.
- 28. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, Lesin VM, Nikolenko SI, Pham S, Prjibelski AD, Pyshkin AV, Sirotkin AV, Vyahhi N, Tesler G, Alekseyev MA, Pevzner PA. 2012. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol 19:455-77.
- 29. Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, Bealer K, Madden TL. 2009. BLAST+: architecture and applications. BMC Bioinformatics 10:421.
- Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, Lopez R, McWilliam H, Remmert M, Soding J, Thompson JD, Higgins DG. 2011. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol Syst Biol 7:539.
- Lepine F, Milot S, Groleau MC, Deziel E. 2018. Liquid Chromatography/Mass Spectrometry (LC/MS) for the Detection and Quantification of N-Acyl-L-Homoserine Lactones (AHLs) and 4-Hydroxy-2-Alkylquinolines (HAQs). Methods Mol Biol 1673:49-59.
- 32. Piochon M, Coulon PML, Caulet A, Groleau M-C, Déziel E, Gauthier C. 2020. Synthesis and antimicrobial activity of *Burkholderia*-related 4-hydroxy-3-methyl-2-alkenylquinolones (HMAQs) and their *N*-oxide counterparts doi:10.26434/chemrxiv.11859144.v1.
- 33. Conrad M, Limpach L. 1887. synthesen von Chinolinderivaten mittelst Acetessigester. Berichte der deutschen chemischen Gesellschaft 20:944-948.
- Salvaggio F, Hodgkinson JT, Carro L, Geddis SM, Galloway WRJD, Welch M, Spring DR. 2016. The Synthesis of Quinolone Natural Products from Pseudonocardia sp. European Journal of Organic Chemistry 2016:434-437.
- 35. Woschek A, Mahout M, Mereiter K, Hammerschmidt F. 2007. Synthesis of 2-Heptyl-1hydroxy-4(1H)-quinolone - Unexpected Rearrangement of 4-(Alkoxycarbonyloxy)quinoline N-Oxides to 1-(Alkoxycarbonyloxy)-4(1H)-quinolones. Synthesis 2007:1517-1522.

- 36. Dulcey CE, Dekimpe V, Fauvelle DA, Milot S, Groleau MC, Doucet N, Rahme LG, Lepine F, Deziel E. 2013. The end of an old hypothesis: the pseudomonas signaling molecules 4-hydroxy-2-alkylquinolines derive from fatty acids, not 3-ketofatty acids. Chem Biol 20:1481-91.
- 37. Agarwal A, Kahyaoglu C, Hansen DB. 2012. Characterization of HmqF, a protein involved in the biosynthesis of unsaturated quinolones produced by Burkholderia thailandensis. Biochemistry 51:1648-57.
- 38. Lepine F, Milot S, Deziel E, He J, Rahme LG. 2004. Electrospray/mass spectrometric identification and analysis of 4-hydroxy-2-alkylquinolines (HAQs) produced by Pseudomonas aeruginosa. J Am Soc Mass Spectrom 15:862-9.
- 39. Diggle SP, Matthijs S, Wright VJ, Fletcher MP, Chhabra SR, Lamont IL, Kong X, Hider RC, Cornelis P, Camara M, Williams P. 2007. The *Pseudomonas aeruginosa* 4-quinolone signal molecules HHQ and PQS play multifunctional roles in quorum sensing and iron entrapment. Chem Biol 14:87-96.
- 40. Lepine F, Deziel E, Milot S, Rahme LG. 2003. A stable isotope dilution assay for the quantification of the Pseudomonas quinolone signal in Pseudomonas aeruginosa cultures. Biochim Biophys Acta 1622:36-41.
- 41. Hays EE, Wells IC, Katzman PA, Cain CK, Jacobs FA, Thayer SA, Doisy EA, Gaby WL, Roberts EC, Muir RD, Carroll CJ, Jones LR, Wade NJ. 1945. Antibiotic Substances produced by Pseu-domonas aeruginosa. Biological Chemistry 159:725-50.
- 42. Diggle SP, Lumjiaktase P, Dipilato F, Winzer K, Kunakorn M, Barrett DA, Chhabra SR, Camara M, Williams P. 2006. Functional genetic analysis reveals a 2-Alkyl-4-quinolone signaling system in the human pathogen Burkholderia pseudomallei and related bacteria. Chem Biol 13:701-10.
- 43. Machan ZA, Taylor GW, Pitt TL, Cole PJ, Wilson R. 1992. 2-Heptyl-4-hydroxyquinoline N-oxide, an antistaphylococcal agent produced by *Pseudomonas aeruginosa*. J Antimicrob Chemother 30:615-23.
- Nguyen AT, Jones JW, Ruge MA, Kane MA, Oglesby-Sherrouse AG. 2015. Iron Depletion Enhances Production of Antimicrobials by Pseudomonas aeruginosa. J Bacteriol 197:2265-75.
- 45. Gallagher LA, McKnight SL, Kuznetsova MS, Pesci EC, Manoil C. 2002. Functions required for extracellular quinolone signaling by Pseudomonas aeruginosa. J Bacteriol 184:6472-80.
- 46. Hooi DS, Bycroft BW, Chhabra SR, Williams P, Pritchard DI. 2004. Differential immune modulatory activity of Pseudomonas aeruginosa quorum-sensing signal molecules. Infect Immun 72:6463-70.
- 47. Deziel E, Lepine F, Milot S, He J, Mindrinos MN, Tompkins RG, Rahme LG. 2004. Analysis of *Pseudomonas aeruginosa* 4-hydroxy-2-alkylquinolines (HAQs) reveals a role

for 4-hydroxy-2-heptylquinoline in cell-to-cell communication. Proc Natl Acad Sci U S A 101:1339-44.

- 48. Bredenbruch F, Geffers R, Nimtz M, Buer J, Haussler S. 2006. The Pseudomonas aeruginosa quinolone signal (PQS) has an iron-chelating activity. Environ Microbiol 8:1318-29.
- 49. Wu Y, Seyedsayamdost MR. 2017. Synergy and Target Promiscuity Drive Structural Divergence in Bacterial Alkylquinolone Biosynthesis. Cell Chem Biol 24:1437-1444 e3.

Tables

			Transposon insertion information	Location
Mutant	Locus	Gene	Predicted function	(bp in gene)
14	BTH_II1935	hmqA	2-aminobenzoate-CoA ligase	1231
27	BTH_II1935	hmqA	2-aminobenzoate-CoA ligase	1513
31	BTH_II1935	hmqA	2-aminobenzoate-CoA ligase	1478
68	BTH_II1933	hmqC	Unknown	783
7	BTH_II1933	hmqF	Polyketide synthase	163
9	BTH_II1930	hmqF	Polyketide synthase	2524
63	BTH_II1930	hmqF	Polyketide synthase	2872
32	BTH_II1576	"hmqL	" Putative monooxygenase	226
56	BTH_II1576	"hmqL"	' Putative monooxygenase	998

Table 1. Location of transposon insertions

			Minimum Inhibitory Concentration ^{b, c}	
Quinolone family ^a	Carbon chain	$[M+H]^+$	B. subtilis	S. aureus
HMAQ	C ₉	284	50	25
HMAQ-NO	C ₉	300	0.75	25
HAQ (HHQ)	C_7	242	>200	>200
HAQ-NO (HQNO)	C_7	259	25	25
HMAQ-NO	C_8	286	1.5	6.25
HMAQ-NO	C_7	272	6.25	12.5

Table 2. Antimicrobial activities of quinolone analogs.

^aAll quinolones had unsaturated carbon chains of the length indicated. HMAQ with a C9 carbon chain (HMAQC9:2') was purified as described in (22). HMAQ-NO congeners were synthesized as described in Materials and Methods and Piochon et al. (32). HAQ-NO with a C₇ carbon chain (HQNO) and HAQ with a C₇ carbon chain (HHQ) were commercially purchased (Cayman Chemicals and Sigma Aldrich, respectively). ^bResults are the averages of three independent experiments. In all cases the range was <5%.

^cNo activity of any of the compounds was observed up to 200 µg/mL against *Pseudomonas aeruginosa* strain PA14 and *Escherichia coli* strain JM109

Figure legends

Figure 1. Sensitivity of *Bacillus subtilis* to a substance produced by *Burkholderia* thailandensis. A) For liquid coculture growth, B subtilis was combined in a 1:1 ratio with either Burkholderia thailandensis E264 (WT) or bactobolin-deficient Burkholderia *thailandensis* (Bacto⁻, strain BD20) in LB broth and grown for 24 h at 37 °C prior to plating to determine surviving colony forming units as described in Materials and Methods. Data are representative of three biological replicates. B) On plates, B. subtilis growth inhibition following treatment with cultures or culture fluid from B. thailandensis after 18 hr of growth. B. thailandensis wild type (E264) or the bactobolin-defective mutant (Bacto, strain BD20) were applied to a lawn of freshly plated B. subtilis and plates were incubated at 30°C prior to imaging. Top panel: B. thailandensis culture fluid was filtered and used to saturate paper diffusion discs applied to the B. subtilis lawn. A zone of clearing around a diffusion disc indicates the region where B. subtilis growth was inhibited. Results are similar to those previously reported (12). Middle panel: Unfiltered B. thailandensis fluid (10 µL) was spotted directly onto B. subtilis. Bottom panel: Unfiltered *B. thailandensis* fluid as in the middle panel was spotted onto a lawn of *B.* subtilis on media containing 5% NaCl, which inhibits B. thailandensis growth.

Figure 2. *B. thailandensis* **transposon mutants with reduced** *Bacillus subtilis* **killing.** A) Unfiltered fluid (5 μl) from *B. thailandensis* stationary-phase cultures was spotted

A) on the red fluid (5 µr) from *B. inditabalensis* stationary-phase cultures was spotted onto a lawn of freshly plated *B. subtilis* and incubated overnight at 30°C. Results are shown as the diameter of the zones of inhibition. The black dashed line indicates the diameter of the spot of *B. thailandensis* culture. Transposon mutant numbers correspond with mutant locations in **Table 1** and are shaded by gene. Dark grey, *hmqA* disruptions; light grey, *hmqC* disruption; white, *hmqF* disruption; hatched, BTH_II1576 disruptions. P (parent), the *B. thailandensis* bactobolin-deficient mutant BD20 used for transposon mutagenesis. Data are the average of two biological replicates. B) Images of *B. subtilis* lawns spotted with 5 ul unfiltered fluid from cultures of the *B. thailandensis* bactobolindeficient strain BD20 or BD20 with disruptions in *hmqA* or BTH_II1576 introduced by homologous recombination. **Figure 3. Biosynthesis of hydroxy-alkylquinolones**. *Burkholderia thailandensis* uses the *hmq* gene products to synthesize hydroxy-alkylquinolones, including HMAQ and HMAQ-NO. In *Pseudomonas aeruginosa*, analogous *pqs* genes synthesize the related compounds HAQ, HAQ-NO and PQS. The R group represents a 5-11 carbon chain that can be saturated or contain a double bond at the 1'-2' position. The *B. thailandensis* compounds are methylated by HmqG, which does not have a homolog in *P. aeruginosa. pqsH* is needed for production of PQS, which is specific to *P. aeruginosa*.

Figure 4. BTH_II1576 (*hmqL*) involvement in HMAQ-NO production and *B. subtilis*

killing. A) HMAQ-NO (C9) was quantified in stationary-phase *B. thailandensis* strains using LC-MS/MS and methods described previously (22). B) Antimicrobial activity of unfiltered *B. thailandensis* fluid (5 μ L) on a lawn of freshly plated *B. subtilis* on plates containing 1 mM IPTG. Strains tested were the *B. thailandensis* bactobolin-deficient BD20 with the IPTG-inducible plac expression cassette inserted into the neutral glmS1 site in the genome (BD20 plac), the constructed BD20 BTH_II1576 (hmqL) mutant with the plac cassette in glmS1 (hmqL⁻ plac), or the BD20 hmqL mutant with plac-hmqL in glmS1 (hmqL⁻ plac-hmqL).


Figure 5. Involvement of BTH_II1576 (*hmqL*) in *B. subtilis* killing in liquid cocultures and its cell pellet fraction localization. A) Results of co-cultures of *B subtilis* combined in a 1:1 ratio with bactobolin-deficient *B. thailandensis* (Bacto[¬]) parent strain or the parent strain bearing a constructed deletion in *hmqA*, *hmqL*, or both in LB broth and grown for 24 h at 37 °C. Surviving colony forming units (CFU) were enumerated by serial dilution and plating on LB agar containing, for *B. subtilis*, 5% NaCl (nonpermissive for *B. thailandensis* growth) and for *B. thailandensis*, 100 μg/mL gentamicin (non-permissive for *B. subtilis*). Data are representative of three biological replicates. B) C9 congeners of HMAQ and HMAQ-NO were quantified in unfiltered and filtered fluid from cell-free *B. thailandensis* cultures as well as in pelleted cells using LC-MS/MS and methods described previously (22).

Figure 6. Heterologous expression of *hmqL* in *Burkholderia ambifaria*. A) HMAQ

and HMAQ-NO in cultures of *B. ambifaria* HSJ1 cells containing either pME6010 or pMP6010-*hmqL*. Results are the average of three biological replicates and represent the sum of the C7, C8, and C9 congeners of each molecule. B) Antimicrobial activity of unfiltered fluid (5 μ L) from cultures of *Burkholderia ambifaria* HSJ1 containing pME6010 or pME6010-*hmqL* spotted onto a freshly spread lawn of *B. subtilis* on plates containing 1 mM IPTG. Plates were imaged after 24 h of incubation at 37 °C.

Figures

Fig. 1.



Wild type Bacto⁻






Fig. 3

